Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Exelixis pens TGR5, ROR target collaboration with BMS

Executive Summary

Marking their sixth deal together, Exelixis Inc. (primarily oncology compounds) has licensed Bristol-Myers Squibb Co. exclusive worldwide rights to develop and sell its preclinical TGR5 agonist XL475 and follow-on compounds for diabetes, plus discovery-stage anti-inflammatory ROR antagonists.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing
    • Includes Contract

Related Companies